Search Results - "O'Connor, Paul W."

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial by Miller, Aaron E, Prof, Wolinsky, Jerry S, Prof, Kappos, Ludwig, MD, Comi, Giancarlo, Prof, Freedman, Mark S, Prof, Olsson, Tomas P, Prof, Bauer, Deborah, MS, Benamor, Myriam, MD, Truffinet, Philippe, MD, O'Connor, Paul W, Prof

“…Summary Background Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting multiple sclerosis. We aimed to assess…”
Get full text

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study by Havrdova, Eva, MD, Galetta, Steven, MD, Hutchinson, Michael, MD, Stefoski, Dusan, MD, Bates, David, MD, Polman, Chris H, MD, O'Connor, Paul W, MD, Giovannoni, Gavin, PhD, Phillips, J Theodore, MD, Lublin, Fred D, MD, Pace, Amy, ScD, Kim, Richard, MD, Hyde, Robert, PhD

“…Summary Background The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting…”
Get full text

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Polman, Chris H, O'Connor, Paul W, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H, Phillips, J. Theodore, Lublin, Fred D, Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…This placebo-controlled, randomized trial of patients with relapsing multiple sclerosis demonstrated benefits of natalizumab (an α 4 integrin antagonist) in…”
Get full text

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" by Polman, Chris H., Reingold, Stephen C., Edan, Gilles, Filippi, Massimo, Hartung, Hans-Peter, Kappos, Ludwig, Lublin, Fred D., Metz, Luanne M., McFarland, Henry F., O'Connor, Paul W., Sandberg-Wollheim, Magnhild, Thompson, Alan J., Weinshenker, Brian G., Wolinsky, Jerry S.

“…New diagnostic criteria for multiple sclerosis integrating magnetic resonance image assessment with clinical and other paraclinical methods were introduced in…”
Get full text

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Miller, David H, Khan, Omar A, Sheremata, William A, Blumhardt, Lance D, Rice, George P.A, Libonati, Michele A, Willmer-Hulme, Allison J, Dalton, Catherine M, Miszkiel, Katherine A, O'Connor, Paul W

“…Natalizumab is an antagonist of α 4 integrin, a very late adhesion antigen that is expressed on the surface of activated lymphocytes and monocytes. In this…”
Get full text

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring by Kappos, Ludwig, Prof, Bates, David, MD, Hartung, Hans-Peter, MD, Havrdova, Eva, MD, Miller, David, MD, Polman, Chris H, MD, Ravnborg, Mads, MD, Hauser, Stephen L, MD, Rudick, Richard A, MD, Weiner, Howard L, MD, O'Connor, Paul W, MD, King, John, MD, Radue, Ernst Wilhelm, MD, Yousry, Tarek, MD, Major, Eugene O, PhD, Clifford, David B, MD

“…Summary Natalizumab is a new treatment option for patients with active relapsing-remitting multiple sclerosis. In phase III studies, natalizumab was highly…”
Get full text

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients by Rudick, Richard A., O'Connor, Paul W., Polman, Chris H., Goodman, Andrew D., Ray, Soma S., Griffith, Nancy M., Jurgensen, Stephanie A., Gorelik, Leonid, Forrestal, Fiona, Sandrock, Alfred W., E. Goelz, Susan

“…Objective Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab‐treated multiple sclerosis…”
Get full text

Emerging therapies in relapsing-remitting multiple sclerosis by Marriott, James J, O'Connor, Paul W

“…Disease modifying therapy (DMT) first became available for relapsing-remitting multiple sclerosis (RRMS) fifteen years ago with the development of the…”
Get more information

Oral versus intravenous steroids for treatment of relapses in multiple sclerosis by Burton, Jodie M, O'Connor, Paul W, Hohol, Marika, Beyene, Joseph

“…This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD006921. DOI:…”
Get more information

Defining the clinical course of multiple sclerosis: The 2013 revisions by Lublin, Fred D, Reingold, Stephen C, Cohen, Jeffrey A, Cutter, Gary R, Sørensen, Per Soelberg, Thompson, Alan J, Wolinsky, Jerry S, Balcer, Laura J, Banwell, Brenda, Barkhof, Frederik, Bebo, Bruce, Calabresi, Peter A, Clanet, Michel, Comi, Giancarlo, Fox, Robert J, Freedman, Mark S, Goodman, Andrew D, Inglese, Matilde, Kappos, Ludwig, Kieseier, Bernd C, Lincoln, John A, Lubetzki, Catherine, Miller, Aaron E, Montalban, Xavier, OʼConnor, Paul W, Petkau, John, Pozzilli, Carlo, Rudick, Richard A, Sormani, Maria Pia, Stüve, Olaf, Waubant, Emmanuelle, Polman, Chris H

“…Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of…”
Get full text

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis by Bar-Or, Amit, Freedman, Mark S, Kremenchutzky, Marcelo, Menguy-Vacheron, Françoise, Bauer, Deborah, Jodl, Stefan, Truffinet, Philippe, Benamor, Myriam, Chambers, Scott, O’Connor, Paul W

“…OBJECTIVE:To investigate the effect of teriflunomide on the efficacy and safety of seasonal influenza vaccine. METHODS:The 2011/2012 seasonal influenza vaccine…”
Get full text

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by MARRIOTT, James J, MIYASAKI, Janis M, GRONSETH, Gary, O'CONNOR, Paul W

“…The chemotherapeutic agent mitoxantrone was approved for use in multiple sclerosis (MS) in 2000. After a review of all the available evidence, the original…”
Get full text

Established disease-modifying treatments in relapsing-remitting multiple sclerosis by Oh, Jiwon, O'Connor, Paul W

“…The purpose of this review is to summarize mechanisms of action, efficacy and safety of established disease-modifying treatments (DMTs) that have been widely…”
Get full text

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring by Kappos, Ludwig, Prof, Bates, David, Prof, Edan, Gilles, Prof, Eraksoy, Mefkûre, MD, Garcia-Merino, Antonio, MD, Grigoriadis, Nikolaos, MD, Hartung, Hans-Peter, Prof, Havrdová, Eva, MD, Hillert, Jan, MD, Hohlfeld, Reinhard, Prof, Kremenchutzky, Marcelo, MD, Lyon-Caen, Olivier, Prof, Miller, Ariel, MD, Pozzilli, Carlo, Prof, Ravnborg, Mads, MD, Saida, Takahiko, MD, Sindic, Christian, Prof, Vass, Karl, MD, Clifford, David B, Prof, Hauser, Stephen, Prof, Major, Eugene O, PhD, O'Connor, Paul W, Prof, Weiner, Howard L, Prof, Clanet, Michel, Prof, Gold, Ralf, Prof, Hirsch, Hans H, Prof, Radü, Ernst-Wilhelm, Prof, Sørensen, Per Soelberg, Prof, King, John, MD

“…Summary Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS)…”
Get full text

Multiple sclerosis in 2014. Progress in MS--classification, mechanisms and treatment by Oh, Jiwon, O'Connor, Paul W

“…Scientific progress in multiple sclerosis (MS) research spanned a number of areas in 2014, including therapeutics, disease classification, risk management, and…”
Get full text

Progress in MS—classification, mechanisms and treatment by Oh, Jiwon, O'Connor, Paul W.

“…Scientific progress in multiple sclerosis (MS) research spanned a number of areas in 2014, including therapeutics, disease classification, risk management, and…”
Get full text

Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis by Oh, Jiwon, O’Connor, Paul W.

“…Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral…”
Get full text

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies by Freedman, Mark S, Wolinsky, Jerry S, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Miller, Aaron E, Thangavelu, Karthinathan, Benamor, Myriam, Truffinet, Philippe, O’Connor, Paul W

“…Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the…”
Get full text

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years by Confavreux, Christian, Li, David K, Freedman, Mark S, Truffinet, Philippe, Benzerdjeb, Hadj, Wang, Dazhe, Bar-Or, Amit, Traboulsee, Anthony L, Reiman, Lucy E, O’Connor, Paul W

“…Background: Teriflunomide, an oral disease-modifying therapy in development for patients with relapsing forms of multiple sclerosis (RMS), was well tolerated…”
Get full text

Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects by Oh, Jiwon, O’Connor, Paul W.

“…A number of novel oral agents are now approved for use in relapsing multiple sclerosis (MS). Among these agents, teriflunomide has shown promise with respect…”
Get full text